` NTBL (Notable Labs Ltd) vs S&P 500 Comparison - Alpha Spread

NTBL
vs
S&P 500

Over the past 12 months, NTBL has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Stocks Performance
NTBL vs S&P 500

Loading
NTBL
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NTBL vs S&P 500

Performance Gap Between NTBL and GSPC
HIDDEN
Show

Performance By Year
NTBL vs S&P 500

Loading
NTBL
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Notable Labs Ltd vs Peers

S&P 500
NTBL
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Notable Labs Ltd
Glance View

Market Cap
390k USD
Industry
Biotechnology

Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

NTBL Intrinsic Value
Not Available
Back to Top